Korean J Physiol Pharmacol.  2024 Nov;28(6):569-576. 10.4196/kjpp.2024.28.6.569.

Norepinephrine triggers glutamatergic long-term potentiation in hypothalamic paraventricular nucleus magnocellular neuroendocrine cells through postsynaptic ββ1-AR/PKA signaling pathway in vitro in rats

• Jin JR
• Zhang ZY
• Chu CP
• Li YZ
• Qiu DL

• KMID: 2560736
• DOI: http://doi.org/10.4196/kjpp.2024.28.6.569

Abstract

Norepinephrine (NE) modulates synaptic transmission and long-term plasticity through distinct subtype adrenergic receptor (AR)-mediated-intracellular signaling cascades. However, the role of NE modulates glutamatergic long-term potentiation (LTP) in the hypothalamic paraventricular nucleus (PVN) magnocellular neuroendocrine cells (MNCs) is unclear. We here investigate the effect of NE on high frequency stimulation (HFS)-induced glutamatergic LTP in rat hypothalamic PVN MNCs in vitro, by whole-cell patch-clamp recording, biocytin staining and pharmacological methods. Delivery of HFS induced glutamatergic LTP with a decrease in N2/N1 ratio in the PVN MNCs, which was enhanced by application of NE (100 nM). HFS-induced LTP was abolished by the blockade of N-methyl-D-aspartate receptors (NMDAR) with D-APV, but it was rescued by the application of NE. NE failed to rescue HFS-induced LTP of MNCs in the presence of a selective β1-AR antagonist, CGP 20712. However, application of β1-AR agonist, dobutamine HCl rescued HFS-induced LTP of MNCs in the absence of NMDAR activity. In the absence of NMDAR activity, NE failed to rescue HFS-induced MNC LTP when protein kinase A (PKA) was inhibited by extracellular applying KT5720 or intracellular administration of PKI. These results indicate that NE activates β1-AR and triggers HFS to induce a novel glutamatergic LTP of hypothalamic PVN NMCs via the postsynaptic PKA signaling pathway in vitro in rats.

Keyword

Adrenergic receptor; Long-term potentiation; Magnocellular neuroendocrine neuron; Paraventricular hypothalamic nucleus; Synaptic transmission

Figure

• 

  Fig. 1 NE enhanced HFS-induced glutamatergic LTP of PVN MNCs. (A) Representative whole-cell recording traces showing paired-pulse stimulation (duration: 0.2 msec, interval: 50 msec) evoked EPSCs in the PVN MNCs before (pre), after (post) delivering HFS (100 pulses, 3 times, 10 sec interval) in treatment with ACSF (left) and NE (100 nM; right). (B) Summary of data showing the normalized amplitude of N1 before and after the delivery of HFS (arrow head) in each treatment. (C, D) Bar graphs show normalized amplitude of N1 (C) and N2/N1 ratio (D) before (pre) and after (post) the delivery of HFS. (E) Biocytin staining showing microscopic image (left, ×4) and enlarged microphotograph (right, ×40) illustrated the morphology of recorded MNC. NE, norepinephrine; HFS, high frequency stimulation; LTP, long-term potentiation; PVN, paraventricular nucleus; MNCs, magnocellular neuroendocrine cells; EPSCs, excitatory postsynaptic currents; ACSF, artificial cerebrospinal fluid. *p < 0.05 vs. pre; #p < 0.05 vs. post of control; n = 7 cells from 5 mice in each group.

• 

  Fig. 2 HFS-induced LTP was abolished by an NMDAR blocker, D-APV, but it was rescued by the application of NE. (A) In the presence of D-APV (50 µM), representative whole-cell recording traces showing paired-pulse stimulation (duration: 0.2 msec, interval: 50 msec) evoked EPSCs in PVN MNCs before (pre), after (post) delivering HFS in treatment with ACSF (control; left) and NE (100 nM; right). (B) Pooled data showing the time course of the normalized amplitude of N1 before and after delivery of HFS (arrow head) during treatment with ACSF and NE. (C, D) Bar graphs show the normalized amplitude of N1 (C) and N2/N1 ratio (D) in each group, before (pre) and after (post) delivery of HFS. HFS, high frequency stimulation; LTP, long-term potentiation; NMDAR, N-methyl-D-aspartate receptors; D-APV, D-(-)-2-Amino-5-phosphonopentanoic acid; NE, norepinephrine; EPSCs, excitatory postsynaptic currents; PVN, paraventricular nucleus; MNCs, magnocellular neuroendocrine cells; ACSF, artificial cerebrospinal fluid. *p < 0.05 vs. pre; #p < 0.05 vs. post of control; n = 7 cells from 6 mice in each group.

• 

  Fig. 3 In the presence of D-APV, the NE-rescued LTP was abolished by β1-AR antagonist. (A) In the presence of D-APV (50 µM), representative whole-cell recording traces showing paired-pulse stimulation (duration: 0.2 msec, interval: 50 msec) evoked EPSCs in PVN MNCs before (pre), after (post) delivering HFS during treatment with NE (100 nM; left) and a mixture of NE (100 nM) + CGP 20712 (1 µM). (B) In the presence of D-APV, pooled data showing the time course of normalized amplitude of N1 before and after the delivery of HFS (arrow head) during treatment with NE and a mixture of NE + CGP 20712. (C, D) Bar graphs show the normalized amplitude of N1 (C) and N2/N1 ratio (D) in each group, before (pre) and after (post) the delivery of HFS. D-APV, D-(-)-2-Amino-5-phosphonopentanoic acid; NE, norepinephrine; LTP, long-term potentiation; AR, adrenergic receptor; EPSCs, excitatory postsynaptic currents; PVN, paraventricular nucleus; MNCs, magnocellular neuroendocrine cells. *p < 0.05 vs. pre; #p < 0.05 vs. post of control; n = 8 cells from 6 mice in each group.

• 

  Fig. 4 HFS-induced LTP was abolished by D-APV, but it was reversed by β1-AR agonist. (A) In the presence of D-APV (50 µM), representative whole-cell recording traces showing paired-pulse stimulation (duration: 0.2 msec, interval: 50 msec) evoked EPSCs in PVN MNCs before (pre), after (post) delivering HFS during treatment with NE (100 nM; left) and a mixture of NE + dobutamine (1 µM; right). (B) Pooled data showing the time course of normalized amplitude of N1 before and after the delivery of HFS (arrow head) during treatment with D-APV (50 µM) and a mixture of D-APV + dobutamine. (C, D) Bar graphs show the normalized amplitude of N1 (C) and N2/N1 ratio (D) in each group, before (pre) and after (post) delivery of HFS. HFS, high frequency stimulation; LTP, long-term potentiation; D-APV, D-(-)-2-Amino-5-phosphonopentanoic acid; AR, adrenergic receptor; EPSCs, excitatory postsynaptic currents; PVN, paraventricular nucleus; MNCs, magnocellular neuroendocrine cells. *p < 0.05 vs. pre; #p < 0.05 vs. post of control; n = 7 cells from 5 mice in each group.

• 

  Fig. 5 In the presence of D-APV and KT5720, NE could not rescue LTP of PVN MNCs. (A) In the presence of D-APV (50 µM), representative whole-cell recording traces showing paired-pulse stimulation (duration: 0.2 msec, interval: 50 msec) evoked EPSCs in PVN MNCs before (pre), after (post) delivering HFS during treatment with NE (100 nM; left) and a mixture of NE (100 nM) + KT5720 (100 nM; right). (B) Pooled data showing the time course of the normalized amplitude of N1 before and after delivery of HFS (arrow head) during treatment with NE and a mixture of NE + KT5720. (C, D) Bar graphs show the normalized amplitude of N1 (C) and N2/N1 ratio (D) in each group, before (pre) and after (post) delivery of HFS. D-APV, D-(-)-2-Amino-5-phosphonopentanoic acid; NE, norepinephrine; LTP, long-term potentiation; PVN, paraventricular nucleus; MNCs, magnocellular neuroendocrine cells; EPSCs, excitatory postsynaptic currents; HFS, high frequency stimulation. *p < 0.05 vs. pre; #p < 0.05 vs. post of control; n = 9 cells from 6 mice in each group.

• 

  Fig. 6 In the presence of D-APV and recording with PKI internal solution, NE could not rescue LTP of PVN MNCs. (A) Representative current traces showing the evoked EPSCs recorded with PKI internal solution from a PVN MNCs before (pre) and after (post) delivering HFS during treatment with D-APV (50 µM) + NE (100 nM). (B) Pooled data showing the time course of normalized amplitude of N1 before and after delivery of HFS (arrow head) during treatment with D-APV + NE. (C, D) Bar graphs show the normalized amplitude of N1 (C) and N2/N1 ratio (D) before (pre) and after (post) delivery of HFS. D-APV, D-(-)-2-Amino-5-phosphonopentanoic acid; PKI, protein kinase inhibitor; NE, norepinephrine; LTP, long-term potentiation; PVN, paraventricular nucleus; MNCs, magnocellular neuroendocrine cells; EPSCs, excitatory postsynaptic currents; HFS, high frequency stimulation. *p < 0.05 vs. pre; #p < 0.05 vs. post of control; n = 6 cells from 5 mice in each group.

Reference

1. Zhang BB, Jin H, Bing YH, Zhang XY, Chu CP, Li YZ, Qiu DL. 2019; A nitric oxide-dependent presynaptic LTP at glutamatergic synapses of the PVN magnocellular neurosecretory cells in vitro in rats. Front Cell Neurosci. 13:283. DOI: 10.3389/fncel.2019.00283. PMID: 31316353. PMCID: PMC6610542.

2. Csáki A, Kocsis K, Halász B, Kiss J. 2000; Localization of glutamatergic/aspartatergic neurons projecting to the hypothalamic paraventricular nucleus studied by retrograde transport of [3H]D-aspartate autoradiography. Neuroscience. 101:637–655. DOI: 10.1016/S0306-4522(00)00411-5. PMID: 11113313.

3. van den Pol AN, Wuarin JP, Dudek FE. 1990; Glutamate, the dominant excitatory transmitter in neuroendocrine regulation. Science. 250:1276–1278. DOI: 10.1126/science.1978759. PMID: 1978759.

4. Decavel C, Van den Pol AN. 1990; GABA: a dominant neurotransmitter in the hypothalamus. J Comp Neurol. 302:1019–1037. DOI: 10.1002/cne.903020423. PMID: 2081813.

5. Wuarin JP, Dudek FE. 1993; Patch-clamp analysis of spontaneous synaptic currents in supraoptic neuroendocrine cells of the rat hypothalamus. J Neurosci. 13:2323–2331. DOI: 10.1523/JNEUROSCI.13-06-02323.1993. PMID: 8099123. PMCID: PMC6576514.

6. Stern JE, Galarreta M, Foehring RC, Hestrin S, Armstrong WE. 1999; Differences in the properties of ionotropic glutamate synaptic currents in oxytocin and vasopressin neuroendocrine neurons. J Neurosci. 19:3367–3375. DOI: 10.1523/JNEUROSCI.19-09-03367.1999. PMID: 10212296. PMCID: PMC6782249.

7. Panatier A, Gentles SJ, Bourque CW, Oliet SH. 2006; Activity-dependent synaptic plasticity in the supraoptic nucleus of the rat hypothalamus. J Physiol. 573:711–721. DOI: 10.1113/jphysiol.2006.109447. PMID: 16613872. PMCID: PMC1779752.

8. Salter EW, Sunstrum JK, Matovic S, Inoue W. 2018; Chronic stress dampens excitatory synaptic gain in the paraventricular nucleus of the hypothalamus. J Physiol. 596:4157–4172. DOI: 10.1113/JP275669. PMID: 29901836. PMCID: PMC6117590.

9. Matsuura T, Kawasaki M, Suzuki H, Fujitani T, Baba K, Nishimura H, Ikeda N, Yamanaka Y, Tsukamoto M, Yoshimi Y, Ohnishi H, Ueta Y, Sakai A. 2023; Nitric oxide synthase contributes to the maintenance of LTP in the oxytocin-mRFP1 neuron of the rat hypothalamus. J Neuroendocrinol. 35:e13340. DOI: 10.1111/jne.13340. PMID: 37776071.

10. Maguire J. 2014; Stress-induced plasticity of GABAergic inhibition. Front Cell Neurosci. 8:157. DOI: 10.3389/fncel.2014.00157. PMID: 24936173. PMCID: PMC4047962.

11. Stanton LM, Price AJ, Manning EE. 2023; Hypothalamic corticotrophin releasing hormone neurons in stress-induced psychopathology: revaluation of synaptic contributions. J Neuroendocrinol. 35:e13268. DOI: 10.1111/jne.13268. PMID: 37078436.

12. Herman JP, Tasker JG. 2016; Paraventricular hypothalamic mechanisms of chronic stress adaptation. Front Endocrinol (Lausanne). 7:137. DOI: 10.3389/fendo.2016.00137. PMID: 27843437. PMCID: PMC5086584.

13. Chappell PB, Smith MA, Kilts CD, Bissette G, Ritchie J, Anderson C, Nemeroff CB. 1986; Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J Neurosci. 6:2908–2914. DOI: 10.1523/JNEUROSCI.06-10-02908.1986. PMID: 3020187. PMCID: PMC6568795.

14. Ma XM, Lightman SL, Aguilera G. 1999; Vasopressin and corticotropin-releasing hormone gene responses to novel stress in rats adapted to repeated restraint. Endocrinology. 140:3623–3632. DOI: 10.1210/endo.140.8.6943. PMID: 10433220.

15. Bartsch JC, von Cramon M, Gruber D, Heinemann U, Behr J. 2021; Stress-induced enhanced long-term potentiation and reduced threshold for N-methyl-D-aspartate receptor- and β-adrenergic receptor-mediated synaptic plasticity in rodent ventral subiculum. Front Mol Neurosci. 14:658465. DOI: 10.3389/fnmol.2021.658465. PMID: 33967694. PMCID: PMC8100191.

16. Chay A, Zamparo I, Koschinski A, Zaccolo M, Blackwell KT. 2016; Control of βAR- and N-methyl-D-aspartate (NMDA) receptor-dependent cAMP dynamics in hippocampal neurons. PLoS Comput Biol. 12:e1004735. DOI: 10.1371/journal.pcbi.1004735. PMID: 26901880. PMCID: PMC4763502.

17. Han SK, Chong W, Li LH, Lee IS, Murase K, Ryu PD. 2002; Noradrenaline excites and inhibits GABAergic transmission in parvocellular neurons of rat hypothalamic paraventricular nucleus. J Neurophysiol. 87:2287–2296. DOI: 10.1152/jn.2002.87.5.2287. PMID: 11976368.

18. Inoshita T, Hirano T. 2021; Norepinephrine facilitates induction of long-term depression through β-adrenergic receptor at parallel fiber-to-Purkinje cell synapses in the flocculus. Neuroscience. 462:141–150. DOI: 10.1016/j.neuroscience.2020.05.037. PMID: 32502572.

19. Cui LN, Sun N, Li BX, Wang LF, Zhang XY, Qiu DL, Chu CP. 2020; Noradrenaline inhibits complex spikes activity via the presynaptic PKA signaling pathway in mouse cerebellar slices. Neurosci Lett. 729:135008. DOI: 10.1016/j.neulet.2020.135008. PMID: 32344107.

20. Wang JY, Weng WC, Wang TQ, Liu Y, Qiu DL, Wu MC, Chu CP. 2023; Noradrenaline depresses facial stimulation-evoked cerebellar MLI-PC synaptic transmission via α2-AR/PKA signaling cascade in vivo in mice. Sci Rep. 13:15908. DOI: 10.1038/s41598-023-42975-5. PMID: 37741947. PMCID: PMC10517918.

21. Yamaguchi N, Mimura K, Okada S. 2019; GABA_B receptors in the hypothalamic paraventricular nucleus mediate β-adrenoceptor-induced elevations of plasma noradrenaline in rats. Eur J Pharmacol. 848:88–95. DOI: 10.1016/j.ejphar.2019.01.029. PMID: 30685430.

22. Domingos-Souza G, Martinez D, Sinkler S, Heesch CM, Kline DD. 2021; Alpha adrenergic receptor signaling in the hypothalamic paraventricular nucleus is diminished by the chronic intermittent hypoxia model of sleep apnea. Exp Neurol. 335:113517. DOI: 10.1016/j.expneurol.2020.113517. PMID: 33132201. PMCID: PMC7750300.

23. Chu CP, Jin WZ, Bing YH, Jin QH, Kannan H, Qiu DL. 2013; Effects of stresscopin on rat hypothalamic paraventricular nucleus neurons in vitro. PLoS One. 8:e53863. DOI: 10.1371/journal.pone.0053863. PMID: 23349753. PMCID: PMC3548845.

24. Tasker JG, Dudek FE. 1991; Electrophysiological properties of neurones in the region of the paraventricular nucleus in slices of rat hypothalamus. J Physiol. 434:271–293. DOI: 10.1113/jphysiol.1991.sp018469. PMID: 2023120. PMCID: PMC1181417.

25. O'Dell TJ, Connor SA, Guglietta R, Nguyen PV. 2015; β-Adrenergic receptor signaling and modulation of long-term potentiation in the mammalian hippocampus. Learn Mem. 22:461–471. DOI: 10.1101/lm.031088.113. PMID: 26286656. PMCID: PMC4561407.

26. Laing M, Bashir ZI. 2014; β-Adrenoceptors and synaptic plasticity in the perirhinal cortex. Neuroscience. 273:163–173. DOI: 10.1016/j.neuroscience.2014.04.070. PMID: 24836853. PMCID: PMC4067743.

27. O'Dell TJ, Connor SA, Gelinas JN, Nguyen PV. 2010; Viagra for your synapses: enhancement of hippocampal long-term potentiation by activation of beta-adrenergic receptors. Cell Signal. 22:728–736. DOI: 10.1016/j.cellsig.2009.12.004. PMID: 20043991. PMCID: PMC2826554.

28. Wang M, Ramasamy VS, Kang HK, Jo J. 2020; Oleuropein promotes hippocampal LTP via intracellular calcium mobilization and Ca₂₊-permeable AMPA receptor surface recruitment. Neuropharmacology. 176:108196. DOI: 10.1016/j.neuropharm.2020.108196. PMID: 32598912.

29. Park P, Georgiou J, Sanderson TM, Ko KH, Kang H, Kim JI, Bradley CA, Bortolotto ZA, Zhuo M, Kaang BK, Collingridge GL. 2021; PKA drives an increase in AMPA receptor unitary conductance during LTP in the hippocampus. Nat Commun. 12:413. DOI: 10.1038/s41467-020-20523-3. PMID: 33462202. PMCID: PMC7814032.